Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: A systematic review and cost-effectiveness analysis

Health Technology Assessment

Volumn 17, Issue 44, 2013, Pages

  Ward, S ^a   Scope, A ^a   Rafia, R ^a   Pandor, A ^a   Harnan, S ^a   Evans, P ^a   Wyld, L ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; TREATMENT OUTCOME;

EID: 84885136402     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17440     Document Type: Article

References (194)

1. Dumitrescu RG, Cotarla I. Understanding breast cancer risk-where do we stand in 2005? J Cell Mol Med 2005;9:208-21.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet 2001;358:1389-99.
3. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993;85:1819-27.
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
5. Lagerros YT, Hsieh SF, Hsieh CC. Physical activity in adolescence and young adulthood and breast cancer risk: a quantitative review. Eur J Cancer Prev 2004;13:5-12.
6. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983;52:1551-7.
7. National Institute for Health and Care Excellence, National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and treatment. Clinical guideline CG80. London: NICE; 2009.
8. Office for National Statistics. Survival rates in England, patients diagnosed 2001-2006 followed up to 2007; 2007. URL: www.statistics.gov.uk/StatBase/Product.asp?vlnk=14007 (last accessed September 2011).
9. West Midlands Cancer Intelligence Unit. 0-10 year relative survival for cases of breast cancer by stage diagnosed in the West Midlands 1985-1989 followed up to the end of 1999, as at January 2002. 2009.
10. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-19.
11. Adjuvant! Online. Adjuvant! Online. Decision making tools for health care professionals; 2009. URL: www.adjuvantonline.com/index.jsp (last accessed September 2011).
12. Cancer Research UK. Cancer statistics: breast cancer UK; 2009. URL: http://publications. cancerresearchuk.org/WebRoot/crukstoredb/CRUK_PDFs/CSBREA09.pdf (last accessed September 2011).
13. Cancer Research UK, National Cancer Intelligence Network. Cancer incidence and survival by major ethnic group, England, 2002-2006; 2009. URL: http://publications.cancerresearchuk. org/WebRoot/crukstoredb/CRUK_PDFs/CR-UKNCIN_ETHNIC.pdf (last accessed September 2011).
14. National Cancer Intelligence Network. Cancer incidence by deprivation England, 1995-2004. URL: www.ncin.org.uk/docs/081202-NCIN-Incidence_by_Deprivation_95_04.pdf (last accessed September 2011)
15. Welsh Cancer Intelligence and Surveillance Unit. Cancer incidence, mortality and survival by deprivation in Wales; 2009. URL: www.wales.nhs.uk/sites3/Documents/242/Deprivation%20 in%20Wales%201993-2007.pdf (last accessed September 2011).
16. Cancer Research UK. Cancer survival and deprivation statistics; 2005. URL: http://info.cancerresearchuk.org/cancerstats/survival/survivaldeprivation (last accessed September 2011).
17. Office for National Statistics. Death registrations in England and Wales, 2008, causes; 2009. URL: www.statistics.gov.uk/pdfdir/dthreg0809.pdf (last accessed September 2011).
18. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ 2000;321:665-9.
19. International Union against Cancer. TNM classification of malignant tumours, 5th edn. New York: Wiley-Liss; 1997.
20. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006;56:37-47.
21. Cancer Research UK. TNM breast cancer staging; 2009. URL: www.cancerhelp.org.uk/help/ default.asp?page=3316 (last accessed September 2011).
22. Agency for Healthcare Research and Quality. Surgery choices for women with early-stage breast cancer; 2009. URL: www.ahrq.gov/consumer/brcanchoice.htm (last accessed September 2011).
23. US National Cancer Institute. Surgery choices for women with early-stage breast cancer; 2009. URL: www.cancer.gov/cancertopics/breast-cancer-surgery-choices (last accessed September 2011).
24. American Cancer Society. How Is Breast Cancer Staged? URL: www.cancer.org/docroot/ CRI/content/CRI_2_4_3X_How_is_breast_cancer_staged_5.asp. 2009 (last accessed August 2011).
25. National Institute for Health and Care Excellence. Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimes in breast cancer management. Final scope. Diagnostics Assessment Programme. London: NICE; 2011.
26. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
27. Genomic Health. Oncotype DX. Information provided by the manufacturers to NICE. 2011.
28. National Institute for Health and Care Excellence. Guidance on cancer services. Improving outcomes in breast cancer. London: NICE; 2011.
29. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2011;365:1687-717.
30. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. Centre for Reviews and Dissemination; 2009. URL: www.york.ac.uk/ inst/crd/systematic_reviews_book.htm (last accessed September 2011).
31. Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
32. National Institute for Health and Care Excellence. NICE Diagnostic Assessment Programme interim methods statement (pilot). London: NICE; 2010.
33. Marchionni L, Wilson R, Marinopoulos S, Wolff A, Parmigiani G, Bass E, et al. Impact of gene expression profiling tests on breast cancer outcomes. Evidence Report/Technology Assessment No. 160. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
34. Smartt P. A comparison of gene expression profiling tests for breast cancer. HSAC Report 3(16). Christchurch, New Zealand: Health Services Assessment Collaboration; 2010.
35. Levine MN, Browman GP, Gent M, Roberts R, Goodyear M. When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 1991;9:348-56.
36. Simon R. A checklist for evaluating reports of expression profiling for treatment selection. Clin Adv Hematol Oncol 2006;4:219-24.
37. Altman D. Systematic reviews in health care: systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224-8.
38. Shea B, Hamel C, Wells G, Bouter L, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62:1013-20.
39. Cronin M, Pho M, Dutta D, Stephans J, Shak S, Kiefer M, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164:35-42.
40. Cronin M, Sangli C, Liu M, Pho M, Dutta D, Nguyen A, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 2007;53:1084-91.
41. Habel L, Shak S, Jacobs M, Capra A, Alexander C, Pho M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8:R25.
42. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
43. Cobleigh M, Tabesh B, Bitterman P, Baker J, Cronin M, Liu M, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005;11:8623-31.
44. Esteva F, Sahin A, Cristofanilli M, Coombes K, Lee S, Baker J, et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005;11:3315-19.
45. Bryant J. Toward a more rational selection of tailored adjuvant therapy. Data from the National Surgical Adjuvant Breast and Bowel Project; Proceedings of the Ninth International St Gallen Breast Cancer Conference, 26-29 January 2005, St Gallen, Switzerland.
46. Hornberger J, Cosler L, Lyman G. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005;11:313-24.
47. Paik S, Shak S, Tang G. Risk classification of breast cancer patients by the recurrence score assay: comparison to guidelines based on patient age, tumor size, and tumor grade. Abstract 104. Paper presented at the Annual San Antonio Breast Cancer Symposium; 2004.
48. Oratz R, Paul D, Cohn A, Sedlacek S. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 2007;3:182-6.
49. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
50. Goldstein L, Gray R, Badve S, Childs B, Yoshizawa C, Rowley S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26:4063-71.
51. Wolf I, Ben Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 2008;112:731-6.
52. Asad J, Jacobson A, Estabrook A, Smith S, Boolbol S, Feldman S, et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 2008;196:527-9.
53. Henry L, Stojadinovic A, Swain S, Prindiville S, Cordes R, Soballe PW. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009;99:319-23.
54. Li L, Xu X, Zhao Y, Liu Z, Shen Z, Jin W, et al. Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res Treat 2009;113:231-7.
55. Rayhanabad J, Difronzo L, Haigh P, Romero L. Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm. Am Surg 2008;74:887-90.
56. Erb C, Fox KR, Patel M, Hook K, DeMichele A, Kaplan C, Domchek S. Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the oncotype DX assay at the University of Pennsylvania. Paper presented at the 30th Annual San Antonio Breast Cancer Symposium, 2007.
57. Gold JM, Najita JS, Lester S, Richardson AL, Morganstern DE, Chen WY, et al. Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. J Clin Oncol 2009;27(Suppl. 15):572.
58. Lo SS, Norton J, Mumby PB, Smerage J, Kash J, Chew HK, et al. Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. J Clin Oncol 2007;25(Suppl. 15):18.
59. Shak S, Palmer G, Baehner FL, Millward C, Watson D, Sledge GW. Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol 2009:27(Suppl. 15):549.
60. Ach R, Floore A, Curry B, Lazar V, Glas A, Pover R, et al. Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics 2007;8:148.
61. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92.
62. Glas A, Floore A, Delahaye L, Witteveen A, Pover R, Bakx N, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278.
63. van't Veer LJ, Dai H, van de Vijver M, He Y, Hart A, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
64. van de Vijver M, He Y, van't Veer L, Dai H, Hart A, Voskuil D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Eng J Med 2002;347:1999-2009.
65. Mook S, Schmidt M, Viale G, Pruneri G, Eekhout I, Floore A, et al. The 70-gene prognosissignature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009;116:295-302.
66. Wittner B, Sgroi D, Ryan P, Bruinsma T, Glas A, Male A, et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 2008;14:2988-93.
67. Bueno-de-Mesquita JM, van Harten W, Retel V, Van't Veer LJ, van Dam F, Karsenberg K, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007;8:1079-87.
68. Bender RA, Knauer M, Rutgers EJ, Glas AM, de Snoo FA, Linn, SC, et al. The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients. J Clin Oncol 2009;27(Suppl. 15):512.
69. de Snoo FA, Knauer M, Bender RA, Stork-Sloots L, Rutgers EJ, Glas AM, et al. Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guidelines. J Clin Oncol 2009;27(Suppl. 15):535.
70. Glas A, de Snoo F, Dreezen C, Roepman P, Bender R, Van 't Veer, L. Use of MammaPrint to identify good prognosis group within clinically indeterminate risk patients. 2008. URL: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=58& abstractID=40205.
71. Knauer M, Mook S, Retèl V, Kok M, Wesseling J, Glas AM, et al. Early determination of metastatic potential in breast cancer: The 70-gene signature in small tumors. J Clin Oncol 2009;27(Suppl. 15):518.
72. Saghatchian M, Mook S, Pruneri G, Viale G, Glas A, Eekhout I, et al. 43LBA Combining genomic profiling (70-gene MammaPrint) with nodal status allows to classify patients with primary breast cancer and positive lymph nodes (1-9) into very distinct prognostic subgroups that could help tailor treatment strategies. Eur J Cancer Suppl 2009;7:19.
73. Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009;99:319-23.
74. Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, et al. Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res Treat 2009;113:231-7.
75. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010;21:717-22.
76. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28:1671-6.
77. Geffen DB, Amir N, Sion-Vardy N, Ariad S, Kachko L, Bayme M, et al. Stage I breast cancer in a regional oncology practice in Israel 2002-2006: clinicopathologic features, risk estimation and planned therapy of 328 consecutive patients. Breast 2009;18:316-21.
78. Holt S, Bertelli G, Pudney D, Rolles M, Moe M, Brinkworth S, et al. Results from a prospective clinical study on the impact of Oncotype DX on adjuvant treatment decision and risk classification by Nottingham prognostic index (NPI) and recurrence score (RS). Breast 2011;(Suppl. 1):s43.
79. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-34.
80. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677-83.
81. Tang G, Shak S, Paik S, Anderson SJ, Costantino JP, Geyer CE, et al. Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127:133-42.
82. Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, et al. The effects of Oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 2011;126:797-802.
83. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
84. Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and Human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-8.
85. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, et al. Utility of Oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010;116:5161-7.
86. Tang G, Constantino J, Crager M, Shak S, Wolmark N. [S4-9] Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score. Proceedings of the 33rd Annual San Antonio Breast Cancer Symposium, 8-12 December, 2010.
87. Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 2010;116:3112-18.
88. Yorozuya K, Takeuchi T, Yoshida M, Mouri Y, Kousaka J, Fujii K, et al. Evaluation of Oncotype DX recurrence score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary stage I or IIA breast cancer. J Cancer Res Clin Oncol 2010;136:939-44.
89. Dundar Y, Dodd S, Dixkson R, Walley T, Haycox A, Williamson PR. Comparison of conference abstracts and presentations with full-text articles in the health technology assessment of rapidly evolving technologies. Health Technol Assess 2006;10(5).
90. Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, et al. Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Cancer Res 2009;69:75S-76S.
91. ClinicalTrials. gov. Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (the TAILORx Trial); 2011. URL: http://clinicaltrials.gov/ct2/show/study/NCT00310180?term=oncotype+dx&r ank=3 (last accessed September 2011).
92. Kunz G. Use of a genomic test (MammaPrint9) in daily clinical practice to assist in risk stratification of young breast cancer patients. Arch Gynecol Obstet 2011;283:597-602.
93. Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DSA, van Krimpen C, et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2009;117:483-95.
94. Gevensleben H, Gohring UJ, Buttner R, Heukamp LC, Kunz G, Dimpfl T, et al. Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer. Int J Mol Med 2010;26:837-43.
95. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
96. Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM, et al. Clinical utility of the 70-gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol 2010;40:508-12.
97. Goldhirsch A, Ingle JN, Gelber R, Coates AS, Thuerlimann B. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2009;20:1319-29.
98. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting Highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90:1601-9.
99. Kok M, Koornstra R, Mook M, Hauptmann M, Fles R, Glas A, et al. Additional value of 70-gene signature and levels of ER and PR in the prediction of outcome from tamoxifentreated ER-positive breast cancer. In The Breast. 2012. doi:10.1016/j.breast.2012.04.010.
100. Na KY, Kim KS, Lee JE, Kim HJ, Yang JH, Ahn SH, et al. The 70-gene prognostic signature for Korean breast cancer patients. J Breast Cancer 2011;14:33-8.
101. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2001;30:5-15.
102. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133e44.
103. Goldhirsch A, Glick JH, Gelber R, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90:1601-9.
104. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. Seventh International Conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001;19:381-727.
105. Nationaal Borstkanker Overleg Nederland. Richtlijn Behandeling van hetMammacarcinoom 2005. 2005. URL:www.oncoline.nl.
106. Kwaliteitsinstituut voor de Gezondheidszorg CBO Vereniging voor Integrale Kankercentra. In Adjuvante Systemische Therapie voor het Operabel Mammacarcinoom. Richtlijn Behandeling van het Mammacarcinoom; 2005. pp. 46-70.
107. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91.
108. Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010;17:1406-13.
109. Bueno-de-Mesquita JM, Sonke G, van der Vijer M, Linn S. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Ann Oncol 2011;22:2012-30.
110. Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJT, et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 2010;103:1788-93.
111. Knauer M, Mook S, Rutgers EJT, Bender RA, Hauptmann M, van de Vijver MJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120:655-61.
112. Knauer M, Mook S, Linn S, van't Veer L, Rutgers E. The 70-gene expression profile as MammaPrint predictive markers for a response to (neo) adjuvant chemotherapy in breast cancer. Onkologie 2010;33:27.
113. Tice JA. The 70-gene signature (MammaPrint) as a guide for the management of early stage breast cancer. San Francisco: California Technology Assessment Forum; 2010. URL: www.ctaf.org/content/assessment/detail/1178 (last accessed September 2011).
114. Stork-Sloots L, Krijgsman O, Roepman P, de Snoo FA, Bender RA, Glas AM. Combining multigene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer. J Clin Oncol 2009;27:15s.
115. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
116. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:5222-32.
117. Cheang M, Voduc D, Tu D, Jiang S, Leung S, Chia SKL, et al. The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC. CTG MA.5 randomized trial. J Clin Oncol 2011;29(Suppl.):A1032.
118. Ebbert M, Bastien R, Rowe L, Miller P, Anderson D, Boucher KM, et al. PAM50 breast cancer intrinsic classifier: clinical validation of a multianalyte laboratory developed test. J Clin Oncol 2011;29(Suppl.):A10597.
119. Bernard PS, Davis C, Munarriz B. Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: validation on GEICAM 9906 clinical trial. J Clin Oncol 2011;29(Suppl.):A611.
120. Martin M, Rodriguez-Lescure A, Stijleman I, Munarriz B, Ruiz-Borrego M, Davis C, et al. PAM50 proliferation index predicts response to weekly adjuvant paclitaxel in node-positive operable breast cancer; 2012. Unpublished.
121. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012;18:4465-72.
122. Jerevall PL, Ma X-J, Li H, Salunga R, Kesty NC, Erlander MG, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 2011;104:1762-9.
123. Randox Laboratories. Information provided by manufacturer to the National Institute for Health and Care Excellence Diagnostic Assessment programme. 2011.
124. Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res 2010;12:R47.
125. Ring B, Seitz R, Beck R, Shasteen W, Tarr S, Cheang M, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3039-47.
126. Ross D, Kim C-Y, Tang G, Bohn O, Beck R, Ring B, et al. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NASBP B14 and B20 trials. Clin Cancer Res 2008;14:6602-9.
127. Bartlett J. Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions. Clin Breast Cancer 2010;10(Suppl. 3):S86-95.
128. Nottingham Prognostics. NPI+. Information provided by the manufacturers to NICE. 2011.
129. National Cancer Comprehensive Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V.2.2010. URL: www.nccn.org/professionals/physician_gls/PDF/ breast.pdf.
130. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-283.
131. Eddy DM. Technology assessment: The role of mathematical modelling. In Assessing Medical Technology. Washington, DC: National Academy Press; 1985. pp. 144-54.
132. Chen E, Tong KB, Malin JL. Cost-effectiveness of 70-gene MammaPrint signature in nodenegative breast cancer. Am J Manag Care 2010;16:E333-42.
133. Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, van Harten WH. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer Suppl 2010;8:1382-91.
134. Medical Advisory Secretariat. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser (Internet); December 2010. URL: www.health.gov.on.ca/english/ providers/program/mas/tech/reviews/pdf/gep_20101213.pdf (last accessed September 2011).
135. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI, Tsoi DT, et al. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 2010;15:457-65.
136. Paulden M, Franek J, Pham B, Krahn M. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: a cost-effectiveness analysis of 1000 strategies for the provision of Adjuvant! Online, Oncotype DX and adjuvant chemotherapy; 2011. URL: http://theta.utoronto.ca/papers/theta_cadth2011_paulden-2.pdf (last accessed September 2011).
137. Hornberger J, Lyman GH, Chien R, Hornberger J, Lyman GH, Chien R. Economic implications of 21-gene recurrence score assay: US multicenter experience. J Clin Oncol 2010;28:e382.
138. Liaropoulos L, Galanis P, Kaitelidou D, Rovithis D, Siskou O, Theodorou P. Gross financial evaluation of the application of the 21-gene assay Oncotype DX for adjuvant chemotherapy decision-making in estrogen receptor-positive node negative breast cancer in Greece. Breast 2011;20:S44.
139. Lopes LF, Bacchi CE, Lopes LF, Bacchi CE. HER-2 status in gastrointestinal stromal tumor. Ann Diagn Pathol 2008;12:283-5.
140. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard K. Cost-effectiveness analysis of Oncotype DX-guided treatment in early breast cancer. J Clin Oncol 2009;27:e11536.
141. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 2010;13:381-7.
142. HAYES, Inc. Oncotype DX for prognosis of breast cancer recurrence (structured abstract). Lansdale, PA: HAYES, Inc.; 2010.
143. Bacchi CE, Prisco F, Carvalho FM, Ojopi EB, Saad ED, Bacchi CE, et al. Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in Brazil. Rev Assoc Med Bras 2010;56:186-91. URL: www.oncologypractice.com/fileadmin/content_images/tor/ issue_archives/2010/ONC_JAN_FEB_2010_lores.pdf.
144. Jancin B. Oncotype DX can predict risk in node-positive patients. Oncol Rep 2010;(January-February):13.
145. Annabi BL. A MT1-MMP/NF-B signaling axis as a checkpoint controller of COX-2 expression in CD133(+) U87 glioblastoma cells. J Neuroinflammation 2008;6:8.
146. Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH, et al. Costeffectiveness of the 70-gene signature versus St Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 2010;46:1382-91.
147. Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008;19:487-95.
148. Lidgren M, Willking N, Jonsson B, Rehnberg C. Health related quality of life in different states of breast cancer. Qual Life Res 2007;16:1073-81.
149. National Cancer Institute. Surveillance, Epidemiology and End Results cancer statistics. May 2009. URL: http://seer.cancer.gov/statistics/ (last accessed 22 December 2009).
150. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
151. Earle CC, Chapman RH, Baker C, Bell CM, Stone PW, Sandberg EA, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-17.
152. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-17.
153. Ara RM, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health 2011;14:539-45.
154. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991;324:160-8.
155. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2001;30:135.
156. Office for National Statistics. 2007-2009 Interim Life Tables. 2010. URL: www.statistics.gov. uk/STATBASE/Product.asp?vlnk=14459 (last accessed on 6 April 2011).
157. Thomas R, Williams M, Marshall C, et al. The total hospital and community UK costs of managing patients with relapsed breast cancer. Br J Cancer 2009;100:598-600.
158. Milne R, Heaton-Brown KH, Hansen P, Thomas D, Harvey V, Cubitt A. Quality-of-life valuations of advanced breast cancer by New Zealand women. Pharmacoeconomics 2006;24:281-92.
159. Peasgood T, Ward SE, Brazier J. Health-state utility values in breast cancer. Exp Rev Pharmacoecon Outcomes Res 2011;10:553-66.
160. Conner-Spady BL, Cumming C, Nabholtz JM, Jacobs P, Stewart D. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 2005;36:251-9.
161. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 61, March 2011. London: BMA and RPS; 2011.
162. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11(12).
163. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007;11(26).
164. Department of Health. NHS reference costs 2009-2010. London: Department of Health; 2010.
165. Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a costeffectiveness and cost-utility analysis. J Clin Oncol 2008;26:925-33.
166. Blohmer JU, Kuhn T, Rezai M, Kummel S, Warm M, Eggemann H, et al. German multicentre decision impact study of Oncotype DX recurrence score (RS) on adjuvant treatment in estrogen receptor positive (ER plus) node negative (N0) and node positive (N plus) early breast cancer. Breast 2011;20:S46.
167. Demichell R. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996;41:177-85.
168. Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. Plos One 2010;5:e8933.
169. Clarient. Mammostrat. Information provided by the manufacturers to NICE. 2011.
170. Rosman M, Mylander WC, Tafra L, Rosman M, Mylander WC, Tafra L. What is the value of the 21 gene recurrence score in HER2-negative patients? J Clin Oncol 2010;28:e647.
171. ARUP Laboratories Inc. PAM50. Information provided by the manufacturers to NICE. 2011.
172. Breast Cancer Clinical Outcome Measures (BCCOM) Project. Analysis of the management of symptomatic breast cancers diagnosed in 2002; 2006. URL: www.wmpho.org.uk/wmciu/ documents/BCCOM_annual_report.pdf (last accessed September 2011).
173. Albanell J, Colomer R, Ruiz-Borrego M, Alba E, Saenz JAG, Martin M, et al. Prospective trans-GEICAM study of the impact of the 21-gene recurrence score assay and traditional clinico-pathological factors on clinical decision making in women with estrogen receptorpositive, HER2-negative, node-negative breast cancer. Breast 2011;20:S43.
174. Gregg X, Belnap T, Rowley B, Rees W. Experience with use of the Oncotype DX gene assay test in a multicenter community-based healthcare system. Cancer Res 2009;69(Suppl. 3):842S.
175. Department of Health. NHS reference costs 2010-2011. London: Department of Health; 2011.
176. Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J. et al. The costeffectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second and third generation regimens for patients with differing prognoses. Eur J Cancer 2011;47:2517-30.
177. Avon, Somerset and Wiltshire NHS Cancer Services. Fluorouracil, epirubicin and cyclophosphamide (FEC75) for early breast cancer. Avon, Somerset and Wiltshire NHS Cancer Services; 2011. URL: www.avon.nhs.uk/aswcs-chemo/STCP/Breast%202009and2010/ FEC75%20ASWCS09%20BR001-Final.pdf (last accessed August 2011).
178. Curtis L. Unit costs of health and social care 2010. Canterbury: PPSRU, University of Kent; 2010. URL: www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf (last accessed September 2011).
179. Roche H, Fumoleau P, Spielmann M, Canon J, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24:5664-71.
180. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005;23:4179-91.
181. Edlin R, Connock M, Round J, Tubeuf S, Fry-Smith A, Hyde C, et al. Azacitidine for the treatment of myelodyplastic syndrome, chronic myelomonocytic leukaemia, and acute myeloid leukaemia. A single technology appraisal. West Midlands Health Technology Assessment Collaboration. 2009. URL: www.nice.org.uk/nicemedia/live/12036/45019/45019.pdf (last accessed September 2011).
182. Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer 2007;97:479-85.
183. Younis T, Rayson D, Skedgel C. Adjuvant chemotherapy in breast cancer: is TC a costeffective regimen compared to AC? 2008. URL: www.abstracts2view.com/sabcs/viewp. php?nu=p6110 (last accessed September 2011).
184. Office for National Statistics. Cancer registration statistics England 2007. Series MB1 no. 38; 2010. URL: www.statistics.gov.uk/StatBase/Product.asp?vlnk=7720&Pos=1&ColRank=1&R ank=272 (last accessed September 2011).
185. de Bock G, Putter H, Bonnema J, van der Hage J, Bartelink H, van de Velde C. The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat 2009;117:401-8.
186. Bueno-de-Mesquita JM. Use of 70-gene signature to predict prognosis of patients with nodenegative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007;8:1079-87.
187. MINDACT trial. Microarray In Node negative Disease may Avoid ChemoTherapy. A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in nodenegative breast cancer. 2011. URL: http://www.eortc.be/services/unit/mindact/documents/ MINDACT_trial_outline.pdf (last accessed 11 September 2012).
188. TAILORx trial. Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (the TAILORx trial). 2011. URL: http://clinicaltrials.gov/ct2/show/study/NCT00310180?term=oncotype+dx&rank=3 (last accessed 11 September 2012).
189. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
190. Schor A, Carvalho F, Ojopi E, Mangabeira A, Saad E, Bacchi C. 21-gene recurrence score (RS) in 100 consecutive Brazilian Patients. Cancer Res 2009;69:842S-843S.
191. Bighin C, Del Mastro L, Canavese G, Carli F, Taveggia P, Levaggi A, et al. Use in current clinical practice of 70-gene signature in early breast cancer. Int J Cancer 2010;127:2736-7.
192. Espinosa E, Sanchez-Navarro I, Gamez-Pozo A, Marin AP, Hardisson D, Madero R, et al. Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer. Plos One 2009;4:5911.
193. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008;14:2601-8.
194. European Organisation for Research and Treatment of Cancer. MINDACT (Microarray In Node negative Disease may Avoid ChemoTherapy). A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer. 2011. URL: www.eortc.be/services/unit/mindact/documents/MINDACT_trial_outline.pdf (last accessed September 2011).